Stock AXPH ALEXANDRIA CO. FOR PHARMACEUTICALS & CHEMICAL INDUSTRIES
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alexandria Co. For Pharmaceuticals & Chemical Industries

Equities

AXPH

EGS38341C011

Pharmaceuticals

End-of-day quote Egyptian Exchange
Other stock markets
 18:00:00 2024-06-02 EDT 		5-day change 1st Jan Change
218.8 EGP 0.00% Intraday chart for Alexandria Co. For Pharmaceuticals & Chemical Industries -8.94% +22.75%
2023 Alexandria Co. For Pharmaceuticals & Chemical Industries Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
2022 Alexandria Co. For Pharmaceuticals & Chemical Industries Reports Earnings Results for the Full Year Ended June 30, 2022 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 775 500.2 633 675.2 529.3 691
Enterprise Value (EV) 1 693.1 337.7 465.3 624.9 384.7 612.5
P/E ratio 8.27 x 5.79 x 4.4 x 5.77 x 4.1 x 5.47 x
Yield 5.81% 9% 12.2% 7.4% - 9.41%
Capitalization / Revenue 1.1 x 0.61 x 0.62 x 0.61 x 0.43 x 0.47 x
EV / Revenue 0.99 x 0.41 x 0.45 x 0.56 x 0.32 x 0.41 x
EV / EBITDA 4.25 x 1.95 x 1.85 x 3.48 x 1.97 x 3.35 x
EV / FCF 47.8 x 2.58 x 8.15 x -28.4 x 2.13 x -37.8 x
FCF Yield 2.09% 38.8% 12.3% -3.52% 46.9% -2.64%
Price to Book 1.78 x 1.04 x 1.11 x 1.15 x 0.86 x 1.05 x
Nbr of stocks (in thousands) 5,000 5,000 5,000 5,000 5,000 5,000
Reference price 2 155.0 100.0 126.6 135.0 105.9 138.2
Announcement Date 8/28/18 8/26/19 8/26/20 9/7/21 9/19/22 10/16/23
1EGP in Million2EGP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 703.7 821.1 1,025 1,111 1,217 1,484
EBITDA 1 163.2 173.2 251.9 179.7 195.7 182.9
EBIT 1 146 153.5 229.5 156.1 169.2 154.9
Operating Margin 20.74% 18.7% 22.39% 14.06% 13.9% 10.44%
Earnings before Tax (EBT) 1 153.9 146.9 220.8 151.6 167.8 164.9
Net income 1 118.2 112.9 170 117 129 126.4
Net margin 16.8% 13.74% 16.59% 10.54% 10.6% 8.52%
EPS 2 18.74 17.27 28.79 23.40 25.80 25.29
Free Cash Flow 1 14.49 131.1 57.08 -22 180.3 -16.18
FCF margin 2.06% 15.96% 5.57% -1.98% 14.82% -1.09%
FCF Conversion (EBITDA) 8.88% 75.68% 22.66% - 92.15% -
FCF Conversion (Net income) 12.26% 116.14% 33.57% - 139.78% -
Dividend per Share 2 9.000 9.000 15.50 10.00 - 13.00
Announcement Date 8/28/18 8/26/19 8/26/20 9/7/21 9/19/22 10/16/23
1EGP in Million2EGP
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 81.9 162 168 50.3 145 78.5
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 14.5 131 57.1 -22 180 -16.2
ROE (net income / shareholders' equity) 29.3% 24.6% 32.3% 20.2% 21.5% 19.9%
ROA (Net income/ Total Assets) 16% 15% 19.3% 12.2% 12.7% 10.8%
Assets 1 738.8 754.2 882.1 957.2 1,018 1,174
Book Value Per Share 2 86.90 96.30 114.0 117.0 123.0 132.0
Cash Flow per Share 2 18.30 33.00 33.50 10.40 30.70 18.10
Capex 1 31.2 13.1 71.2 120 31.8 84.2
Capex / Sales 4.43% 1.6% 6.95% 10.8% 2.62% 5.68%
Announcement Date 8/28/18 8/26/19 8/26/20 9/7/21 9/19/22 10/16/23
1EGP in Million2EGP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ALEXANDRIA CO. FOR PHARMACEUTICALS & CHEMICAL INDUSTRIES Stock Alexandria Co. For Pharmaceuticals & Chemical Industries
+22.75% 23.21M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.60% 748B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.34% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.74% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.79% 325B
ABBVIE INC. Stock AbbVie Inc.
+3.37% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.47% 245B
NOVARTIS AG Stock Novartis AG
+9.26% 211B
ROCHE HOLDING AG Stock Roche Holding AG
-5.07% 209B
AMGEN INC. Stock Amgen Inc.
+6.74% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AXPH Stock
  4. Financials Alexandria Co. For Pharmaceuticals & Chemical Industries